KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Income towards Parent Company (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Income towards Parent Company data on record, last reported at -$40.4 million in Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 1802.7% year-over-year to -$40.4 million; the TTM value through Dec 2025 reached -$546.4 million, down 76.34%, while the annual FY2025 figure was -$546.4 million, 76.34% down from the prior year.
  • Income towards Parent Company reached -$40.4 million in Q4 2025 per PACB's latest filing, down from -$38.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $16.5 million in Q3 2021 and bottomed at -$426.1 million in Q1 2025.
  • Average Income towards Parent Company over 5 years is -$80.3 million, with a median of -$69.6 million recorded in 2021.
  • Peak YoY movement for Income towards Parent Company: soared 169.77% in 2021, then plummeted 1802.7% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at -$69.3 million in 2021, then fell by 21.71% to -$84.4 million in 2022, then increased by 2.8% to -$82.0 million in 2023, then surged by 102.89% to $2.4 million in 2024, then tumbled by 1802.7% to -$40.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were -$40.4 million in Q4 2025, -$38.0 million in Q3 2025, and -$41.9 million in Q2 2025.